Literature DB >> 11112677

Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora.

P Richard1, M H Delangle, F Raffi, E Espaze, H Richet.   

Abstract

We assessed the risk factors for acquisition of fluoroquinolone-resistant, gram-negative organisms in the gastrointestinal tract of hospitalized patients. We analyzed stool samples from 204 patients and recovered fluoroquinolone-resistant, gram-negative organisms from 63. Receipt of fluoroquinolone during the month preceding admission was the only risk factor identified, whereas female sex, duration of hospitalization, exposure to indwelling devices, admission from another hospital, and history of infection were risk factors for fecal colonization after day 4.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112677     DOI: 10.1086/317551

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

1.  Prophylactic treatment of anthrax with antibiotics.

Authors:  C A Hart; N J Beeching
Journal:  BMJ       Date:  2001-11-03

2.  Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.

Authors:  Anne-Sylvie Kesteman; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

3.  Risk factors for fecal quinolone-resistant Escherichia coli in Mexican children.

Authors:  Mussaret B Zaidi; Emma Zamora; Pilar Diaz; Linda Tollefson; Paula J Fedorka-Cray; Marcia L Headrick
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

4.  Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin.

Authors:  Shannon D Putnam; John W Sanders; David R Tribble; David R Rockabrand; Mark S Riddle; Patrick J Rozmajzl; Robert W Frenck
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

6.  Role of hospital stay and antibiotic use on Pseudomonas aeruginosa gastrointestinal colonization in hospitalized patients.

Authors:  D Lepelletier; N Caroff; D Riochet; P Bizouarn; A Bourdeau; F Le Gallou; E Espaze; A Reynaud; H Richet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-09       Impact factor: 3.267

7.  Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission.

Authors:  Victoire de Lastours; Françoise Chau; Florence Tubach; Blandine Pasquet; Etienne Ruppé; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

8.  Emergence and acquisition of fluoroquinolone-resistant gram-negative bacilli in the intestinal tracts of mice treated with fluoroquinolone antimicrobial agents.

Authors:  Michael J Pultz; Michelle M Nerandzic; Usha Stiefel; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

9.  Risk factors for efflux pump overexpression in fluoroquinolone-resistant Escherichia coli.

Authors:  Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Warren B Bilker; Ebbing Lautenbach
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

10.  Temporal changes in resistance mechanisms in colonizing Escherichia coli isolates with reduced susceptibility to fluoroquinolones.

Authors:  Jennifer H Han; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Warren B Bilker; Ebbing Lautenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2013-05-27       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.